Obesity and the kidney: mechanistic links and therapeutic advances
The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.
Abstract
Obesity is strongly associated with the development of diabetes mellitus and chronic kidney disease (CKD), but there is evidence for a bidirectional relationship wherein the kidney also acts as a key regulator of body weight. In this Review, we highlight the mechanisms implicated in obesity-related CKD, and outline how the kidney might modulate feeding and body weight through a growth differentiation factor 15-dependent kidney-brain axis. The favourable effects of bariatric surgery on kidney function are discussed, and medical therapies designed for the treatment of diabetes mellitus that lower body weight and preserve kidney function independent of glycaemic lowering, including sodium-glucose cotransporter 2 inhibitors, incretin-based therapies and metformin, are also reviewed. In summary, we propose that kidney function and body weight are related in a bidirectional fashion, and that this interrelationship affects human health and disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, GLP-1 receptor agonists favorably influence relevant risk factors for kidney disease, including hyperglycemia, elevated blood pressure, and increased body weight (19).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [19]
In the citing paper
“Systemic hypertension has been linked to the development of obesity-related CKD26, but we observed a direct relationship between decreases in systolic BP and decreases in eGFR at multiple time points.”
In the citing paper
“Obesity can contribute to CKD through multiple mechanisms including volume expansion (leading to glomerular hyperfiltration) and the effect of adipocytokines (leptin and aldosterone) to cause renal injury and fibrosis23,26.”
Citations
Cites
2 retracted
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279 · cited 1×
“Network meta-analyses have demonstrated that GLP1RAs, particularly semaglutide, are highly effective for weight management, with a body weight change of 5.8% from baseline over a median of 24 weeks 94 .”
InfluentialRetractedTargeting the NLRP3 inflammasome to Reduce Diet-induced Metabolic Abnormalities in Mice
Chiazza, F., Couturier-Maillard, A., Benetti, E., Mastrocola, R., Nigro, D., Cutrin, J. C., Serpe, L., Aragno, M., Fantozzi, R., Ryffel, B., et al. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00104 · Cited by 80 · cited 1×
“NLRP3 gain-of-function diabetic mice display glomerular injury and albuminuria 43 , while NLRP3 deficiency or pharmacological inhibition in mice with obesity or DKD decreases the accumulation of renal lipid droplets in association with a reduction in inflammation, fibrosis and albuminuria 49,50 .”
RetractedAbarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482 · cited 2×
“If current trends continue, by 2025, approximately 18% of men and 21% of women worldwide will have obesity 1 .”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 3×
“Unexpectedly, however, considerable benefits predominantly on heart failure and kidney outcomes were consistently observed across trials in patients with different levels of cardiovascular and kidney risk 66,67 .”
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668 · cited 2×
“Bariatric surgery remains the most effective intervention for sustained weight loss over a decade 53 .”
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Epidemiology of chronic kidney disease: an update 2022
Kovesdy, C. P. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.003 · Cited by 2,973 · cited 2×
“Paralleling the increasing rates of obesity, the prevalence of chronic kidney disease (CKD) has also risen; CKD affected more than 800 million people worldwide in 2017, and remains a leading cause of morbidity and mortality 2 .”
Empagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754 · cited 3×
“Unexpectedly, however, considerable benefits predominantly on heart failure and kidney outcomes were consistently observed across trials in patients with different levels of cardiovascular and kidney risk 66,67 .”
InfluentialPathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583 · cited 1×
“…does have limitations, including the inability to distinguish between muscle and adipose tissue, and between different types of adipose tissue; this limitation is meaningful because visceral adiposity confers a greater risk of metabolic syndrome and CVD than does subcutaneous adiposity 5 .”
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208 · cited 3×
“The term ‘cardiovascular– kidney–metabolic syndrome’ has been defined as a disorder related to the interaction of obesity, diabetes mellitus, CKD and CVD 4 .”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP1R signalling in feeding and the regulation of body weight is initiated in the paraventricular nucleus and the dorsal vagal complex of the brain 98,99 .”
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Cardiovascular outcome trials have demonstrated that this class of agents reduces the risk of major adverse cardiovascular events in individuals with T2DM compared with placebo 93 .”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“…might underlie differences in body weight loss potency and affect passage across the blood–brain barrier; smaller and longer-acting GLP1RAs, such as liraglutide and semaglutide, potentially have a more potent effect on the central regulation of appetite than larger, shorter-acting GLP1RAs 102 .”
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“Secondary analyses of cardiovascular outcome trials have found that GLP1RAs reduce albuminuria 103 .”
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Obesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.305697 · Cited by 1,360 · cited 17×
“Obesity alters kidney function through multiple mechanisms, including activation of the RSNS, stimulation of the RAAS, secretion of adi-pokines, glomerular hyperfiltration, direct renal lipotoxicity, systemic hypertension, and a distinct entity known as ORG.”
InfluentialCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“Feedback to the macula densa results in afferent vasoconstriction via adenosine, reducing intraglomerular hypertension and preventing long-term glomerular injury in individuals with type 1 diabetes mellitus (T1DM) and hyperfiltration 68 .”
Self-citationObesity-related glomerulopathy: An emerging epidemic
Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J., & D'Agati, V. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041498.x · Cited by 1,286 · cited 11×
“Obesity alters kidney function through multiple mechanisms, including activation of the RSNS, stimulation of the RAAS, secretion of adi-pokines, glomerular hyperfiltration, direct renal lipotoxicity, systemic hypertension, and a distinct entity known as ORG.”
InfluentialMIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamily
Bootcov, M. R., Bauskin, A. R., Valenzuela, S. M., Moore, A. G., Bansal, M., He, X. Y., Zhang, H. P., Donnellan, M., Mahler, S., Pryor, K., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11514 · Cited by 1,177 · cited 1×
“GDF15 is a divergent member of the transforming growth factor-β superfamily 127,128 that is expressed in the liver, kidney and intestine, and mediates the integrated stress response 126,129–131 .”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 1×
“…weekly doses found that treatment with the highest dose (12 mg) resulted in a −24.2% least-squares mean percentage change in body weight at 48 weeks (compared with −2.1% in the placebo group), supporting further potential efficacy for weight loss with the addition of glucagon receptor agonism 113 .”
InfluentialReceptor-mediated regional sympathetic nerve activation by leptin.
Haynes, W. G., Morgan, D. A., Walsh, S. A., Mark, A. L., & Sivitz, W. I. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119532 · Cited by 979 · cited 1×
“Decreased levels of leptin might also result in anti-hypertensive effects by reducing RSNS and RAAS activation 28,39,40,60 .”
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975 · cited 1×
“…‘thrifty substrate’ hypothesis, which postulates that ketogenesis induced by SGLT2is alters metabolism to utilize β-hydroxybutyrate instead of fatty acids as an oxidation substrate in the heart and kidney, thereby improving oxygen consumption efficiencies and mediating cardioprotective effects 72 .”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“Additional results indicate that the GLP1RA liraglutide is internalized upon binding to the GLP1R and alters hypo-thalamic neurons to affect energy balance 100 , while GLPR signalling in the nucleus of the solitary tract is necessary for liraglutide to reduce feeding and weight 101 .”
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Miller, R. A., Chu, Q., Xie, J., Foretz, M., Viollet, B., & Birnbaum, M. J. (2013) · Nature · doi:10.1038/nature11808 · Cited by 833 · cited 1×
“Metformin is a first-line therapy for T2DM that lowers glucose levels primarily by lowering hepatic glucose production 124 .”
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Pathologic classification of focal segmental glomerulosclerosis: a working proposal
D'Agati, V. D., Fogo, A. B., Bruijn, J. A., & Jennette, J. C. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.10.024 · Cited by 776 · cited 1×
“Focal segmental glomerulosclerosis (FSGS) is a histopathological pattern of injury characterized by segmental scarring of the glomerular capillary tuft with accumulation of extracellular matrix 11 .”
GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates
Mullican, S. E., Lin-Schmidt, X., Chin, C.-N., Chavez, J. A., Furman, J. L., Armstrong, A. A., Beck, S. C., South, V. J., Dinh, T. Q., Cash-Mason, T. D., et al. (2017) · Nature Medicine · doi:10.1038/nm.4392 · Cited by 774
Weight loss and health status 3 years after bariatric surgery in adolescents
Inge, T. H., Courcoulas, A. P., Jenkins, T. M., Michalsky, M. P., Helmrath, M. A., Brandt, M. L., Harmon, C. M., Zeller, M. H., Chen, M. K., Xanthakos, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506699 · Cited by 750 · cited 1×
“Beyond weight loss, bariatric surgery can induce remission of diabetes mellitus, normalize blood pressure and attenuate the progression of obesity-related CKD 54–56 .”
Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
D'Agati, V. D., Chagnac, A., de Vries, A. P. J., Levi, M., Porrini, E., Herman-Edelstein, M., & Praga, M. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.75 · Cited by 716 · cited 3×
“A number of discoveries have implicated a role for kidney-derived growth differentiation factor 15 (GDF15) in regulating weight in the hindbrain 9 .”
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693 · cited 1×
“GFRAL is almost exclusively expressed in the area postrema and nucleus of the solitary tract of the hindbrain 132–135, 138 and Similar to GLP1RAs, GDF15 alters food preferences in individuals with obesity and contributes to reduced caloric intake in mice 131,132,139,140 .”
The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL
Emmerson, P. J., Wang, F., Du, Y., Liu, Q., Pickard, R. T., Gonciarz, M. D., Coskun, T., Hamang, M. J., Sindelar, D. K., Ballman, K. K., et al. (2017) · Nature Medicine · doi:10.1038/nm.4393 · Cited by 675 · cited 1×
“GFRAL is almost exclusively expressed in the area postrema and nucleus of the solitary tract of the hindbrain 132–135, 138 and Similar to GLP1RAs, GDF15 alters food preferences in individuals with obesity and contributes to reduced caloric intake in mice 131,132,139,140 .”
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand
Yang, L., Chang, C.-C., Sun, Z., Madsen, D., Zhu, H., Padkjær, S. B., Wu, X., Huang, T., Hultman, K., Paulsen, S. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4394 · Cited by 668
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654 · cited 3×
“…RAAS, as visceral adipose tissue contains angiotensinogen, the levels of which increase in parallel with increasing BMI and leptin levels; however, whether the downstream production of angiotensin II (Ang-II) is substantial enough to influence obesity-related hypertension remains uncertain 20,21 .”
Non-Homeostatic Body Weight Regulation Through a Brainstem-Restricted Receptor for GDF15
Hsu, J.-Y., Crawley, S., Chen, M., Ayupova, D. A., Lindhout, D. A., Higbee, J., Kutach, A., Joo, W., Gao, Z., Fu, D., et al. (2017) · Nature · doi:10.1038/nature24042 · Cited by 616 · cited 14×
“The mechanism(s) responsible for the weight-lowering effect of metformin remain controversial, although GDF15 and its hindbrain receptor, glial-derived neurotrophic factor receptor ɑ -like (GFRAL), have been implicated as potential mediators 9,125,126 .”
InfluentialTruncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · cited 11×
“However, tubuloglomerular feedback is not a major mechanism by which GLP1RAs mediate their benefit in the kidney, as infusion with the GLP1RA exenatide does not alter renal haemodynamics in patients with T2DM despite increasing proximal sodium excretion 108 .”
InfluentialAdiponectin regulates albuminuria and podocyte function in mice
Sharma, K., RamachandraRao, S., Qiu, G., Usui, H. K., Zhu, Y., Dunn, S. R., Ouedraogo, R., Hough, K., McCue, P., Chan, L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32691 · Cited by 612 · cited 3×
“Adiponectin promotes fatty acid oxidation, and levels of this hormone are suppressed in states of high-fat feeding and obesity 33,34 .”
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589 · cited 1×
“…of this altered metabolism with SGLT2i treatment on the use of free fatty acids in preference to glucose is a reduction in lipid metabolites, thereby maintaining podocyte health by reducing insulin resistance as well as reducing oxidative stress, inflammation and fibrosis in the kidney 88 .”
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584 · cited 6×
“The mechanism(s) responsible for the weight-lowering effect of metformin remain controversial, although GDF15 and its hindbrain receptor, glial-derived neurotrophic factor receptor ɑ -like (GFRAL), have been implicated as potential mediators 9,125,126 .”
InfluentialTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 2×
“Tirzepatide is a GLP1R and GIPR imbalanced dual agonist that preferentially activates the GIPR 110 .”
Obesity-induced Hypertension: Role of Sympathetic Nervous System, Leptin, and Melanocortins
Hall, J. E., da Silva, A. A., do Carmo, J. M., Dubinion, J., Hamza, S., Munusamy, S., Smith, G., & Stec, D. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.113175 · Cited by 528 · cited 3×
“As mentioned above, increased levels of leptin are associated with hypertension via RSNS activation 28,38 and RAAS activation 21,39,40 .”
Obesity, hypertension, and chronic kidney disease
Hall, J., Juncos, L., Wang, Z., Hall, M., do Carmo, J., & da Silva, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s39739 · Cited by 520
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease
Wang, D., Day, E. A., Townsend, L. K., Djordjevic, D., Jørgensen, S. B., & Steinberg, G. R. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00529-7 · Cited by 516 · cited 2×
“GDF15 is a divergent member of the transforming growth factor-β superfamily 127,128 that is expressed in the liver, kidney and intestine, and mediates the integrated stress response 126,129–131 .”
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · cited 1×
“GLP1RAs occurs through central effects that reduce energy intake by decreasing appetite and calorie intake, and promoting satiety 95–97 .”
GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans
Patel, S., Alvarez-Guaita, A., Melvin, A., Rimmington, D., Dattilo, A., Miedzybrodzka, E. L., Cimino, I., Maurin, A.-C., Roberts, G. P., Meek, C. L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.016 · Cited by 509 · cited 4×
“Metformin might increase GDF15 levels through the eIF2α–ATF4–CHOP axis, as the expression of kidney-derived Gdf15 , Chop and ATF4 protein is upregulated in metformin-treated rodents 9,126 ; however, future studies investigating the potential mechanisms underlying the regulation of Gdf15 are warranted (Fig.”
InfluentialFatty kidney: emerging role of ectopic lipid in obesity-related renal disease
de Vries, A. P. J., Ruggenenti, P., Ruan, X. Z., Praga, M., Cruzado, J. M., Bajema, I. M., D'Agati, V. D., Lamb, H. J., Barlovic, D. P., Hojs, R., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70065-8 · Cited by 500 · cited 1×
“…lipids within the kidney (owing to increased lipid storage as a consequence of excessive dietary fat intake), termed ‘renal lipotoxicity’, is implicated in ORG; renal lipotoxicity is observed as a collection of lipid droplets in podocytes, mesangial cells and proximal tubular epithelial cells 41 .”
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1299 · Cited by 494 · cited 1×
“Metformin also results in appreciable weight loss in individuals with or without diabetes mellitus, with a weight reduction of 2.1 ± 5.7% observed in the Diabetes Prevention Program 51,52 .”
InfluentialXu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 493 · cited 1×
“In response to SGLT2i treatment, augmentation of adipose tissue browning via the induction of polarization of M2 macrophages in the white adipose tissue and the liver is observed, resulting in increased energy expenditure 89 .”
Pathophysiological role of leptin in obesity-related hypertension
Aizawa-Abe, M., Ogawa, Y., Masuzaki, H., Ebihara, K., Satoh, N., Iwai, H., Matsuoka, N., Hayashi, T., Hosoda, K., Inoue, G., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8341 · Cited by 477 · cited 1×
“As mentioned above, increased levels of leptin are associated with hypertension via RSNS activation 28,38 and RAAS activation 21,39,40 .”
The tubular hypothesis of nephron filtration and diabetic kidney disease
Vallon, V., & Thomson, S. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0256-y · Cited by 465 · cited 1×
“The tubular hypothesis postulates that SGLT2is confer kidney benefit through reduced energy expenditure on proximal tubule transport, thereby reducing renal cortical oxygen consumption 71 .”
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442 · cited 1×
“In terms of more direct effects in the kidney, GLP1RAs have been shown to inhibit the sodium–hydrogen exchanger 3 in the proximal renal tubule 107 .”
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397 · cited 1×
“GLP1RAs occurs through central effects that reduce energy intake by decreasing appetite and calorie intake, and promoting satiety 95–97 .”
Huby, A.-C., Antonova, G., Groenendyk, J., Gomez-Sanchez, C. E., Bollag, W. B., Filosa, J. A., & de Chantemèle, E. J. B. (2015) · Circulation · doi:10.1161/circulationaha.115.018226 · Cited by 376 · cited 2×
“As mentioned above, increased levels of leptin are associated with hypertension via RSNS activation 28,38 and RAAS activation 21,39,40 .”
Tomita, I., Kume, S., Sugahara, S., Osawa, N., Yamahara, K., Yasuda-Yamahara, M., Takeda, N., Chin-Kanasaki, M., Kaneko, T., Mayoux, E., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.020 · Cited by 376 · cited 1×
“In mouse models, mTOR1C1 overactivation, which reduces autophagic flux, results in impaired renal lipolysis and downstream kidney damage, which can be abrogated by SGLT2i-mediated increases in the production of ketone bodies 90 .”
van Bommel, E. J. M., Muskiet, M. H. A., van Baar, M. J. B., Tonneijck, L., Smits, M. M., Emanuel, A. L., Bozovic, A., Danser, A. H. J., Geurts, F., Hoorn, E. J., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.013 · Cited by 363 · cited 1×
“…T2DM and preserved kidney function, the RED trial found that the SGLTi dapagliflozin reduces GFR without affecting renal vascular resistance, suggesting that post-glomerular efferent arteriolar vasodilation might be the underlying haemodynamic mechanism leading to benefit in this population 69 .”
Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
Ferrannini, G., Hach, T., Crowe, S., Sanghvi, A., Hall, K. D., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-0355 · Cited by 359
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 348 · cited 1×
“If sustained, this negative energy balance would be expected to result in the loss of 7 kg over a 6-month period, although this loss might be offset by a compensatory increase in the consumption of carbohydrate-rich foods 75,76 .”
Self-citationPhysiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4656-5 · Cited by 348 · cited 1×
“SGLT2 is predominantly expressed in the S1 and S2 segments of the proximal tubule, where it functions as a sodium-dependent glucose transporter to reabsorb up to 90% of glucose from the glomerular filtrate; consequently, its inhibition results in glucosuria and calorie loss 64 .”
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
The Nephrotic Syndrome: A Complication of Massive Obesity
WEISINGER, J. R., KEMPSON, R. L., ELDRIDGE, F. L., & SWENSON, R. S. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-440 · Cited by 318 · cited 1×
“In a seminal study in 1974, proteinuria was observed to remit with weight loss in four patients with obesity and nephrotic syndrome 10 .”
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316 · cited 1×
“Endogenous amylin is co-secreted with insulin and has roles in delaying gastric emptying, inhibiting glucagon release and reducing appetite 120 ; the combination of a long-acting amylin analogue, cagrilintide, and semaglutide resulted in greater weight loss than semaglutide alone 121 .”
Schiavon, C. A., Bersch-Ferreira, A. C., Santucci, E. V., Oliveira, J. D., Torreglosa, C. R., Bueno, P. T., Frayha, J. C., Santos, R. N., Damiani, L. P., Noujaim, P. M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032130 · Cited by 308
Yamamoto, T., Takabatake, Y., Takahashi, A., Kimura, T., Namba, T., Matsuda, J., Minami, S., Kaimori, J.-Y., Matsui, I., Matsusaka, T., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016070731 · Cited by 307 · cited 1×
“In podocytes, NLRP3 inflammasome activation impairs autophagy and promotes the accumulation of phospholipids in dysfunctional lysosomes, leading to tubular injury 44,48”
Day, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. M., Lu, R., Raphenya, A. R., Kabiri, M., McArthur, A. G., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0146-4 · Cited by 307 · cited 13×
“However, tubuloglomerular feedback is not a major mechanism by which GLP1RAs mediate their benefit in the kidney, as infusion with the GLP1RA exenatide does not alter renal haemodynamics in patients with T2DM despite increasing proximal sodium excretion 108 .”
InfluentialHeerspink, H. J. L., Sattar, N., Pavo, I., Haupt, A., Duffin, K. L., Yang, Z., Wiese, R. J., Tuttle, K. R., & Cherney, D. Z. I. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00243-1 · Cited by 306 · cited 1×
“In the SURPASS-4 trial, tirzepatide reduced the UACR and attenuated the rate of eGFR decline meaningfully compared with insulin glargine 111 .”
Self-citationClinical features and long‐term outcome of obesity‐associated focal segmental glomerulosclerosis
Praga, M., Hernández, E., Morales, E., Campos, A. P., Valero, M. A., Martínez, M. A., & León, M. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.9.1790 · Cited by 287 · cited 2×
“This lower degree of proteinuria is probably related to the indolent development of proteinuria in secondary FSGS related to glomerular hyperfiltration in the setting of obesity 16 .”
GDF15 promotes weight loss by enhancing energy expenditure in muscle
Wang, D., Townsend, L. K., DesOrmeaux, G. J., Frangos, S. M., Batchuluun, B., Dumont, L., Kuhre, R. E., Ahmadi, E., Hu, S., Rebalka, I. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06249-4 · Cited by 262 · cited 1×
“…GDF15 mediates weight loss in mice through a GFRAL–β-adrenergic receptor signalling pathway that counteracts compensatory reductions in energy expenditure (in response to reduced intake) in skeletal muscle 136 as well as via delayed gastric emptying 137 and enhanced adipose tissue browning 141 .”
Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
Seifarth, C., Schehler, B., & Schneider, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1327734 · Cited by 258 · cited 1×
“Metformin also results in appreciable weight loss in individuals with or without diabetes mellitus, with a weight reduction of 2.1 ± 5.7% observed in the Diabetes Prevention Program 51,52 .”
InfluentialHan, Y.-C., Tang, S.-Q., Liu, Y.-T., Li, A.-M., Zhan, M., Yang, M., Song, N., Zhang, W., Wu, X.-Q., Peng, C.-H., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04184-8 · Cited by 257 · cited 1×
“In addition, metformin-induced AMPK activation in the kidneys of diabetic mice leads to enhanced autophagy and mitophagy in association with decreased markers of tubulointerstitial fibrosis, oxidative stress and mitochondrial damage 145 .”
Adverse renal consequences of obesity
Griffin, K. A., Kramer, H., & Bidani, A. K. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00324.2007 · Cited by 256
Cherney, D. Z. I., Cooper, M. E., Tikkanen, I., Pfarr, E., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Lund, S. S. (2018) · Kidney International · doi:10.1016/j.kint.2017.06.017 · Cited by 243 · cited 1×
“Although impaired kidney function, such as is seen in individuals with CKD, attenuates the magnitude of glucosuria with SGLT2i treatment, weight loss is independent of this glycaemic lowering 87 .”
Self-citationRossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad009 · Cited by 242 · cited 1×
“109).”
NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism
Chrysovergis, K., Wang, X., Kosak, J., Lee, S.-H., Kim, J. S., Foley, J. F., Travlos, G., Singh, S., Baek, S. J., & Eling, T. E. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.27 · Cited by 241 · cited 1×
“…GDF15 mediates weight loss in mice through a GFRAL–β-adrenergic receptor signalling pathway that counteracts compensatory reductions in energy expenditure (in response to reduced intake) in skeletal muscle 136 as well as via delayed gastric emptying 137 and enhanced adipose tissue browning 141 .”
Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237
Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys
Xiong, Y., Walker, K., Min, X., Hale, C., Tran, T., Komorowski, R., Yang, J., Davda, J., Nuanmanee, N., Kemp, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8732 · Cited by 236 · cited 2×
“Injection of recombinant GDF15 or GDF15 overexpression lowers food intake and body weight in lean and obese mice as well as in monkeys through the activation of its receptor, GFRAL 132–137 .”
Renal injury in the extremely obese patients with normal renal function
Serra, A., Romero, R., Lopez, D., Navarro, M., Esteve, A., Perez, N., Alastrue, A., & Ariza, A. (2008) · Kidney International · doi:10.1038/sj.ki.5002796 · Cited by 235 · cited 1×
“Whereas most individuals with obesity have apparently ‘normal’ renal function according to serum levels of creatinine, in a study of kidney biopsy samples taken from individuals undergoing bariatric surgery, 38% of the patients had subclinical pathological glomerular lesions 17 .”
Chang, A. R., Grams, M. E., Ballew, S. H., Bilo, H., Correa, A., Evans, M., Gutierrez, O. M., Hosseinpanah, F., Iseki, K., Kenealy, T., et al. (2019) · BMJ · doi:10.1136/bmj.k5301 · Cited by 233
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.094 · Cited by 223 · cited 1×
“If sustained, this negative energy balance would be expected to result in the loss of 7 kg over a 6-month period, although this loss might be offset by a compensatory increase in the consumption of carbohydrate-rich foods 75,76 .”
Self-citationPlasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action
Eddy, A. A., & Fogo, A. B. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050503 · Cited by 222 · cited 1×
“31) and resistin 32 .”
Romero-Gómez, M., Lawitz, E., Shankar, R. R., Chaudhri, E., Liu, J., Lam, R. L. H., Kaufman, K. D., Engel, S. S., Bruzone, S. O., Coronel, M. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.013 · Cited by 220
Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta
Lawton, L. N., Bonaldo, M. D. F., Jelenc, P. C., Qiu, L., Baumes, S. A., Marcelino, R. A., de Jesus, G. M., Wellington, S., Knowles, J. A., Warburton, D., et al. (1997) · Gene · doi:10.1016/s0378-1119(97)00485-x · Cited by 207 · cited 1×
“GDF15 is a divergent member of the transforming growth factor-β superfamily 127,128 that is expressed in the liver, kidney and intestine, and mediates the integrated stress response 126,129–131 .”
Epoxy-Keto Derivative of Linoleic Acid Stimulates Aldosterone Secretion
Goodfriend, T. L., Ball, D. L., Egan, B. M., Campbell, W. B., & Nithipatikom, K. (2004) · Hypertension · doi:10.1161/01.hyp.0000113294.06704.64 · Cited by 205 · cited 1×
“In animal models, leptin induces aldosterone secretion, while, independent of Ang-II, adipocytes are able to stimulate aldosterone production through polyunsaturated fatty acids (such as linoleic acid) and adipokines, including C1q TNF-related protein (CTRP1) 22,23 .”
Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02033-5 · Cited by 202
High salt intake reprioritizes osmolyte and energy metabolism for body fluid conservation
Kitada, K., Daub, S., Zhang, Y., Klein, J. D., Nakano, D., Pedchenko, T., Lantier, L., LaRocque, L. M., Marton, A., Neubert, P., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88532 · Cited by 201 · cited 2×
“The increased energy needed for the production and accumulation of urea osmolytes results in a reprioritization of energy expenditure, and explains why further weight loss is not observed with chronic SGLT2i use despite ongoing glucosuria 86 .”
Ohashi, K., Iwatani, H., Kihara, S., Nakagawa, Y., Komura, N., Fujita, K., Maeda, N., Nishida, M., Katsube, F., Shimomura, I., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.147645 · Cited by 200 · cited 1×
“Compared with wild-type mice, adiponectin-knockout mice exhibit increased albuminuria and decreased podocyte integrity 34 , glo-merulomegaly and tubulointerstitial fibrosis 35 , whereas administering adiponectin ameliorates these effects 36 .”
Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy
Qiu, Y.-Y., & Tang, L.-Q. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.004 · Cited by 195 · cited 3×
“45).”
Podocyte Lesions in Patients With Obesity-Related Glomerulopathy
Chen, H.-M., Liu, Z.-H., Zeng, C.-H., Li, S.-J., Wang, Q.-W., & Li, L.-S. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.07.025 · Cited by 192 · cited 2×
“Altered structural and functional properties of glomeruli in ORG compromise podocyte integrity and lead to proteinuria, and nephrosclerosis occurs due to the limited ability of mature podocytes to regenerate 13 .”
Growth Differentiation Factor–15 and Risk of CKD Progression
Nair, V., Robinson-Cohen, C., Smith, M. R., Bellovich, K. A., Bhat, Z. Y., Bobadilla, M., Brosius, F., de Boer, I. H., Essioux, L., Formentini, I., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016080919 · Cited by 191 · cited 1×
“Furthermore, patients with stage 3–5 CKD had circulating levels of GDF15 that were approximately twofold higher than those of control individuals 150 .”
A genetic map of the mouse dorsal vagal complex and its role in obesity
Ludwig, M. Q., Cheng, W., Gordian, D., Lee, J., Paulsen, S. J., Hansen, S. N., Egerod, K. L., Barkholt, P., Rhodes, C. J., Secher, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00363-1 · Cited by 186 · cited 1×
“GLP1R signalling in feeding and the regulation of body weight is initiated in the paraventricular nucleus and the dorsal vagal complex of the brain 98,99 .”
Increased renal metabolism in diabetes. Mechanism and functional implications
Körner, A., Eklöf, A.-C., Celsi, G., & Aperia, A. (1994) · Diabetes · doi:10.2337/diab.43.5.629 · Cited by 185 · cited 1×
“In diabetic rats, treatment with the non-selective SGLTi phlorizin reduced renal blood flow, Na + /K + -ATPase activity and oxygen consumption 70 .”
Böttner, M., Suter-Crazzolara, C., Schober, A., & Unsicker, K. (1999) · Cell and Tissue Research · doi:10.1007/s004410051337 · Cited by 180 · cited 1×
“GDF15 is a divergent member of the transforming growth factor-β superfamily 127,128 that is expressed in the liver, kidney and intestine, and mediates the integrated stress response 126,129–131 .”
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
Central Resistin Overexposure Induces Insulin Resistance Through Toll-Like Receptor 4
Benomar, Y., Gertler, A., De Lacy, P., Crépin, D., Ould Hamouda, H., Riffault, L., & Taouis, M. (2013) · Diabetes · doi:10.2337/db12-0237 · Cited by 177 · cited 1×
“31) and resistin 32 .”
GLP-1/glucagon receptor co-agonism for treatment of obesity
Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H. (2017) · Diabetologia · doi:10.1007/s00125-017-4354-8 · Cited by 175 · cited 1×
“Triple agonists that target GLP1, GIP and glucagon receptors with the aim of further reducing food intake and weight loss are under evaluation 112 .”
Ansary, T. M., Nakano, D., & Nishiyama, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030629 · Cited by 174 · cited 1×
“Although SGLT2is induce osmotic diuresis through glucosuria and accompanying sodium natriuresis, long-term diuresis with SGLT2i treatment is not observed owing to adaptive responses by the RAAS and vasopressin systems 82 .”
Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease
Shahzad, K., Fatima, S., Khawaja, H., Elwakiel, A., Gadi, I., Ambreen, S., Zimmermann, S., Mertens, P. R., Biemann, R., & Isermann, B. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.010 · Cited by 172 · cited 6×
“In patients with advanced DKD, metformin reduces albuminuria and progression to ESKD, but might rarely be associated with lactic acidosis in advanced CKD; thus, the benefit of metformin in this context remains controversial 143 .”
InfluentialGrowth Differentiation Factor 15 as a Novel Biomarker for Metformin
Gerstein, H. C., Pare, G., Hess, S., Ford, R. J., Sjaarda, J., Raman, K., McQueen, M., Lee, S., Haenel, H., & Steinberg, G. R. (2017) · Diabetes Care · doi:10.2337/dc16-1682 · Cited by 169 · cited 1×
“Of the 237 biomarkers that were evaluated, GDF15 had the strongest association with metformin use 142 .”
A novel adipokine CTRP1 stimulates aldosterone production
Jeon, J. H., Kim, K., Kim, J. H., Baek, A., Cho, H., Lee, Y. H., Kim, J. W., Kim, D., Han, S. H., Lim, J., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-9412com · Cited by 168
Lee, M., Katerelos, M., Gleich, K., Galić, S., Kemp, B. E., Mount, P. F., & Power, D. A. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018010050 · Cited by 165 · cited 1×
“The renoprotective effects of metformin have been attributed to reduced lipid accumulation and reduced fibrosis via the activation of AMPK signalling 144 .”
ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria
Mallamaci, F., Ruggenenti, P., Perna, A., Leonardis, D., Tripepi, R., Tripepi, G., Remuzzi, G., & Zoccali, C. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010090969 · Cited by 157 · cited 1×
“A post hoc analysis of the REIN trial found that the increased risk of ESKD in individuals with obesity compared with individuals without obesity was mitigated by treatment with the angiotensin-converting enzyme inhibitor ramipril 24 .”
Adipokines as a link between obesity and chronic kidney disease
Briffa, J. F., McAinch, A. J., Poronnik, P., & Hryciw, D. H. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00263.2013 · Cited by 153 · cited 1×
“In contrast to the levels of adiponectin, circulating levels of leptin are increased in obesity and are associated with kidney injury, consistent with its pro-inflammatory, profibrotic and hypertensive effects 37 .”
Shyangdan, D. S., Uthman, O. A., & Waugh, N. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-009417 · Cited by 149 · cited 1×
“Although these agents were designed for the treatment of T2DM, they only modestly improve glycaemic control, lowering HbA 1c by 0.5–1.0% on average 65 .”
InfluentialGLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Górriz, J. L., Soler, M. J., Navarro-González, J. F., García-Carro, C., Puchades, M. J., D’Marco, L., Martínez Castelao, A., Fernández-Fernández, B., Ortiz, A., Górriz-Zambrano, C., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040947 · Cited by 144
Boyle, C. N., Lutz, T. A., & Le Foll, C. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2017.11.009 · Cited by 142 · cited 1×
“Endogenous amylin is co-secreted with insulin and has roles in delaying gastric emptying, inhibiting glucagon release and reducing appetite 120 ; the combination of a long-acting amylin analogue, cagrilintide, and semaglutide resulted in greater weight loss than semaglutide alone 121 .”
Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men
Schorr, U., Blaschke, K., Turan, S., Distler, A., & Sharma, A. M. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816100-00011 · Cited by 141 · cited 1×
“…RAAS, as visceral adipose tissue contains angiotensinogen, the levels of which increase in parallel with increasing BMI and leptin levels; however, whether the downstream production of angiotensin II (Ang-II) is substantial enough to influence obesity-related hypertension remains uncertain 20,21 .”
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Marton, A., Kaneko, T., Kovalik, J., Yasui, A., Nishiyama, A., Kitada, K., & Titze, J. M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00350-x · Cited by 141 · cited 2×
“During this aestivation-like state, the metabolic rate decreases 83 and organic osmolytes counteract osmotic diuresis to maintain hydration status via urea gradient-driven water reabsorption 84 , ureagenesis in the liver and muscle resulting in increased energy expenditure 85 , and alteration in…”
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127 · cited 1×
“Additional results indicate that the GLP1RA liraglutide is internalized upon binding to the GLP1R and alters hypo-thalamic neurons to affect energy balance 100 , while GLPR signalling in the nucleus of the solitary tract is necessary for liraglutide to reduce feeding and weight 101 .”
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126 · cited 1×
“However, tubuloglomerular feedback is not a major mechanism by which GLP1RAs mediate their benefit in the kidney, as infusion with the GLP1RA exenatide does not alter renal haemodynamics in patients with T2DM despite increasing proximal sodium excretion 108 .”
Docherty, N. G., & le Roux, C. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0323-4 · Cited by 115 · cited 1×
“Collectively, these mechanisms might contribute to the preserved glomerular function observed following bariatric surgery, ultimately decreasing albuminuria and the development of CKD 7,63 .”
Benichou, O., Coskun, T., Gonciarz, M. D., Garhyan, P., Adams, A. C., Du, Y., Dunbar, J. D., Martin, J. A., Mather, K. J., Pickard, R. T., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.12.011 · Cited by 115 · cited 3×
“…studies, potentially owing to subtle differences between the synthetic long-acting agonist and endogenous GDF15–GFRAL signalling, a compensatory decrease in energy expenditure, or other experimental design factors such as standardized meals that do not reflect typical eating behaviour 151,158 .”
Heiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano-Lobo, J., Håkansson Gladh, A., Seeley, R. J., Drucker, D. J., Bäckhed, F., & Olofsson, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109163 · Cited by 114
The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease
Kwon, S., Kim, Y. C., Park, J. Y., Lee, J., An, J. N., Kim, C. T., Oh, S., Park, S., Kim, D. K., Oh, Y. K., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0936 · Cited by 113 · cited 1×
“In patients with advanced DKD, metformin reduces albuminuria and progression to ESKD, but might rarely be associated with lactic acidosis in advanced CKD; thus, the benefit of metformin in this context remains controversial 143 .”
Update on the NCEP ATP-III emerging cardiometabolic risk factors
Eckel, R. H., & Cornier, M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-115 · Cited by 106 · cited 3×
“The term ‘cardiovascular– kidney–metabolic syndrome’ has been defined as a disorder related to the interaction of obesity, diabetes mellitus, CKD and CVD 4 .”
Obesity-Related Glomerulopathy in China: A Case Series of 90 Patients
Chen, H., Li, S., Chen, H., Wang, Q., Leishi, L., & Liu, Z.-H. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.303 · Cited by 106
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kaneko, K., Fu, Y., Lin, H.-Y., Cordonier, E. L., Mo, Q., Gao, Y., Yao, T., Naylor, J., Howard, V., Saito, K., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126107 · Cited by 106 · cited 1×
“The mechanism(s) responsible for the metabolic benefits of GLP1R-based polyagonists remain largely unknown, although, in addition to the weight-lowering effect of GLP1, bidirectional changes in GIP and glucagon signalling in the brain also alter feeding and weight 114–118 .”
Impact of Leptin-Mediated Sympatho-Activation on Cardiovascular Function in Obese Mice
Belin de Chantemèle, E. J., Mintz, J. D., Rainey, W. E., & Stepp, D. W. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.168427 · Cited by 103
Nlrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation
Bakker, P. J., Butter, L. M., Kors, L., Teske, G. J. D., Aten, J., Sutterwala, F. S., Florquin, S., & Leemans, J. C. (2013) · Kidney International · doi:10.1038/ki.2013.503 · Cited by 101 · cited 1×
“NLRP3 gain-of-function diabetic mice display glomerular injury and albuminuria 43 , while NLRP3 deficiency or pharmacological inhibition in mice with obesity or DKD decreases the accumulation of renal lipid droplets in association with a reduction in inflammation, fibrosis and albuminuria 49,50 .”
GFRAL-expressing neurons suppress food intake via aversive pathways
Sabatini, P. V., Frikke-Schmidt, H., Arthurs, J., Gordian, D., Patel, A., Rupp, A. C., Adams, J. M., Wang, J., Beck Jørgensen, S., Olson, D. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021357118 · Cited by 100
Frikke-Schmidt, H., Hultman, K., Galaske, J. W., Jørgensen, S. B., Myers, M. G., & Seeley, R. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.003 · Cited by 97 · cited 3×
“In addition, liraglutide maintains its anorectic effect in GDF15-deficient or GFRAL-deficient mice, while GDF15 maintains its anorectic effect in GLP1R-deficient mice 140 .”
Zhang, S., Bruce, K., Danaei, Z., Li, R. J. W., Barros, D. R., Kuah, R., Lim, Y.-M., Mariani, L. H., Cherney, D. Z. I., Chiu, J. F. M., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.014 · Cited by 97
Self-citationImprovement and stabilization of chronic kidney disease after gastric bypass
Alexander, J. W., Goodman, H. R., Hawver, L. R. M., & Cardi, M. A. (2008) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2008.08.016 · Cited by 91 · cited 1×
“Beyond weight loss, bariatric surgery can induce remission of diabetes mellitus, normalize blood pressure and attenuate the progression of obesity-related CKD 54–56 .”
Lu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91 · cited 1×
“Surprisingly, given the efficacy of GLP1R and GIPR dual agonists, a phase I study of AMG133, a bispecific molecule that agonizes GLP1R and antagonizes GIPR in vitro, has shown promising results in inducing weight loss 119 .”
Rivas, L. V., Cuarental, L., Ceballos, M. I., Chocano, A. P., Pérez-Gómez, M. V., Sanz, A. B., Ortíz, A., & Sánchez-Niño, M. D. (2022) · Kidney International · doi:10.1016/j.kint.2022.02.028 · Cited by 90 · cited 5×
“…in kidney injury attenuates markers of renal inflammation, cell death and fibrosis 148 ; GDF15 could upregulate or sustain the expression of Klotho, an anti-inflammatory and antifibrotic protein that is abundantly expressed in the kidney but downregulated in rodent models of kidney injury 148 .”
InfluentialCatheter-Based Radiorefrequency Renal Denervation Lowers Blood Pressure in Obese Hypertensive Dogs
Henegar, J. R., Zhang, Y., Rama, R. D., Hata, C., Hall, M. E., & Hall, J. E. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu048 · Cited by 89 · cited 1×
“The renal sympathetic nerve system (RSNS) also contributes to hypertension in obesity, as established by the amelioration of obesity-related hypertension in response to renal denervation in dogs 26 .”
Kim, S., Soltani-Bejnood, M., Quignard-Boulange, A., Massiera, F., Teboul, M., Ailhaud, G., Kim, J. H., Moustaid-Moussa, N., & Voy, B. H. (2006) · BioMed Research International · doi:10.1155/jbb/2006/27012 · Cited by 87 · cited 1×
“Thus, RAAS inhibition remains a cornerstone of treatment in obesity-associated hypertension 25 .”
Yano, Y., Hoshide, S., Ishikawa, J., Hashimoto, T., Eguchi, K., Shimada, K., & Kario, K. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.07321.x · Cited by 80 · cited 3×
“Beyond improving insulin resistance, adiponectin might also directly preserve podocyte integrity, given the negative correlation between adiponectin and albuminuria in obesity 27,33 .”
Mazagova, M., Buikema, H., van Buiten, A., Duin, M., Goris, M., Sandovici, M., Henning, R. H., & Deelman, L. E. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00387.2013 · Cited by 80 · cited 3×
“The ability of metformin to increase the levels of Gdf15 in the kidney might mediate some of its renoprotective benefits 147,148 .”
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80
NLRP3 inflammasome negatively regulates podocyte autophagy in diabetic nephropathy
Hou, Y., Lin, S., Qiu, J., Sun, W., Dong, M., Xiang, Y., Wang, L., & Du, P. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.194 · Cited by 79 · cited 1×
“In podocytes, NLRP3 inflammasome activation impairs autophagy and promotes the accumulation of phospholipids in dysfunctional lysosomes, leading to tubular injury 44,48”
Yasui, A., Lee, G., Hirase, T., Kaneko, T., Kaspers, S., von Eynatten, M., & Okamura, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0385-5 · Cited by 75 · cited 1×
“…rate decreases 83 and organic osmolytes counteract osmotic diuresis to maintain hydration status via urea gradient-driven water reabsorption 84 , ureagenesis in the liver and muscle resulting in increased energy expenditure 85 , and alteration in cardiovascular energetics, all of which are…”
Morbid obesity and hypertension: The role of perirenal fat
Ricci, M. A., Scavizzi, M., Ministrini, S., De Vuono, S., Pucci, G., & Lupattelli, G. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13370 · Cited by 72 · cited 1×
“Furthermore, decreases in both renal sinus adipose tissue and perirenal adipose tissue have been associated with remission of hypertension following bariatric surgery 61,62 .”
Xu, X., Huang, X., Zhang, L., Huang, X., Qin, Z., & Hua, F. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02391-1 · Cited by 70 · cited 3×
“Beyond improving insulin resistance, adiponectin might also directly preserve podocyte integrity, given the negative correlation between adiponectin and albuminuria in obesity 27,33 .”
The Effects of Bariatric Surgery on Renal Outcomes: a Systematic Review and Meta-analysis
Bilhă, Ş., Nistor, I., Nedelcu, A., Kanbay, M., Scripcariu, V., Timofte, D. V., Siriopol, D. C., & Covic, A. C. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3416-4 · Cited by 69 · cited 8×
“Large meta-analyses have found that elevated BMI, waist circumference and waist to height ratio are independent risk factors associated with loss of kidney function (referring to the overall role of the kidney in maintaining homeostasis) and mortality in individuals with normal or reduced estimated glomerular filtrati…”
InfluentialChemoreflex physiology and implications for sleep apnoea: insights from studies in humans
Mansukhani, M. P., Wang, S., & Somers, V. K. (2015) · Experimental Physiology · doi:10.1113/expphysiol.2014.082826 · Cited by 67 · cited 1×
“…of adiponectin 27 and increased levels of leptin 28 in mice with obesity compared with those without, and to hypoxaemia and hypercapnia from obstructive sleep apnoea in humans with obesity resulting in activation of carotid body chemoreceptors and an increase in sympathetic nerve activity 29 .”
Horie, I., Abiru, N., Hongo, R., Nakamura, T., Ito, A., Haraguchi, A., Natsuda, S., Sagara, I., Ando, T., & Kawakami, A. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.11.016 · Cited by 67 · cited 1×
“In diet-induced obese rats, dapagliflozin treatment was accompanied by compensatory hyperphagia, which attenuated the magnitude of weight loss, and in adult humans, dapagliflozin treatment leads to an increase in daily sucrose intake 77 .”
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 66 · cited 1×
“bioelectrical impedance analysis over 18 months 74 .”
Self-citationZhao, J., Rui, H., Yang, M., Sun, L., Dong, H., & Cheng, H. (2019) · Mediators of Inflammation · doi:10.1155/2019/3172647 · Cited by 64 · cited 1×
“Leptin might promote the formation of lipid droplets through upregulation of the fatty acid transporter CD36, leading to a pro-inflammatory response mediated by activation of the NLRP3 inflammasome 42 .”
Jungnik, A., Arrubla Martinez, J., Plum‐Mörschel, L., Kapitza, C., Lamers, D., Thamer, C., Schölch, C., Desch, M., & Hennige, A. M. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14948 · Cited by 63
Hypothalamic CaMKKβ mediates glucagon anorectic effect and its diet-induced resistance
Quiñones, M., Al-Massadi, O., Gallego, R., Fernø, J., Diéguez, C., López, M., & Nogueiras, R. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.014 · Cited by 60 · cited 1×
“The mechanism(s) responsible for the metabolic benefits of GLP1R-based polyagonists remain largely unknown, although, in addition to the weight-lowering effect of GLP1, bidirectional changes in GIP and glucagon signalling in the brain also alter feeding and weight 114–118 .”
Wild, J., Jung, R., Knopp, T., Efentakis, P., Benaki, D. C., Grill, A., Wegner, J., Molitor, M., Garlapati, V. S., Rakova, N., et al. (2021) · Acta Physiologica · doi:10.1111/apha.13628 · Cited by 60 · cited 1×
“…83 and organic osmolytes counteract osmotic diuresis to maintain hydration status via urea gradient-driven water reabsorption 84 , ureagenesis in the liver and muscle resulting in increased energy expenditure 85 , and alteration in cardiovascular energetics, all of which are outlined below.”
Zhang, Y., Zhao, X., Dong, X., Zhang, Y., Zou, H., Jin, Y., Guo, W., Zhai, P., Chen, X., & Kharitonenkov, A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.001 · Cited by 60 · cited 1×
“This finding was replicated in monkeys, in which reduction in body weight, suppression of food intake and improvement in glycaemic control and insulin secretion were observed alongside few gastrointestinal adverse effects 164 .”
The NLPR3 inflammasome and obesity‐related kidney disease
Ke, B., Shen, W., Fang, X., & Wu, Q. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13333 · Cited by 55 · cited 2×
“Hyperglycaemia and hyperlipidaemia in obesity activate the inflammasome through damage-associated stimuli, including reactive oxygen species, endoplasmic reticulum stress and mitochondrial damage 45,46 .”
Effect of bariatric surgery on plasma GDF15 in humans
Kleinert, M., Bojsen-Møller, K. N., Jørgensen, N. B., Svane, M. S., Martinussen, C., Kiens, B., Wojtaszewski, J. F. P., Madsbad, S., Richter, E. A., & Clemmensen, C. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00010.2019 · Cited by 52 · cited 1×
“In a study in 47 individuals with and without diabetes mellitus who underwent Roux-en-Y gastric bypass, circulating levels of GDF15 increased within 1 week of surgery and remained elevated after 4 years, correlating with the degree of body weight loss 156 .”
Ghidewon, M., Wald, H. S., McKnight, A. D., De Jonghe, B. C., Breen, D. M., Alhadeff, A. L., Borner, T., & Grill, H. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14663 · Cited by 51 · cited 3×
“However, GDF15 might induce weight loss through mechanisms that are distinct from those induced by GLP1RAs 140,162 .”
Metabolic injury-induced NLRP3 inflammasome activation dampens phospholipid degradation
Rampanelli, E., Orsó, E., Ochodnický, P., Liebisch, G., Bakker, P. J., Claessen, N., Butter, L. M., Weerman, M. A. V. D. B., Florquin, S., Schmitz, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01994-9 · Cited by 50 · cited 1×
“In tubular epithelial cells, activation of the NLRP3 inflammasome inhibits a sirtuin 1–AMPK–lipid catabolism pathway, which increases the accumulation of lipids in the tubules and drives cellular damage 47 .”
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50 · cited 1×
“In addition to conferring beneficial effects on glycaemic control, GLP1RAs have positive effects on vascular function and lipid profile as well as reducing blood pressure and appearing to attenuate the process of atherosclerosis 92 .”
Self-citationParadoxical insights into whole body metabolic adaptations following SGLT2 inhibition
Cefalu, W. T. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74297 · Cited by 46 · cited 1×
“Therefore, an alternative hypothesis to explain the steady state of weight loss achieved with SGLT2is might be that weight loss itself results in metabolic adaptations that lead to lower energy expenditure to compensate for the energy lost through glucosuria 81 .”
Metabolic surgery improves renal injury independent of weight loss: a meta-analysis
Scheurlen, K. M., Probst, P., Kopf, S., Nawroth, P. P., Billeter, A. T., & Müller-Stich, B. P. (2019) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2019.03.013 · Cited by 44 · cited 1×
“A meta-analysis found that improvements in albuminuria after bariatric surgery were not correlated with changes in weight or glucose levels, suggesting that bariatric surgery can improve kidney function independent of weight loss and glycaemic control 58 .”
Camptothecin effectively treats obesity in mice through GDF15 induction
Lu, J. F., Zhu, M., Xie, B., Shi, X., Liu, H., Zhang, R. X., Xia, B., & Wu, J. W. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001517 · Cited by 41 · cited 14×
“The mechanism(s) responsible for the weight-lowering effect of metformin remain controversial, although GDF15 and its hindbrain receptor, glial-derived neurotrophic factor receptor ɑ -like (GFRAL), have been implicated as potential mediators 9,125,126 .”
InfluentialMoritz, E., Dadson, P., Saukko, E., Honka, M., Koskensalo, K., Seppälä, K., Pekkarinen, L., Moriconi, D., Helmiö, M., Salminen, P. T. P., et al. (2022) · Metabolites · doi:10.3390/metabo12070617 · Cited by 41 · cited 2×
“Consistent with the postulated direct compressive effects of increased renal adipose tissue on renal vasculature and tissue to alter tubular flow and sodium reabsorption 21 , the amount of renal sinus adipose tissue is negatively associated with eGFR in obesity 61 .”
Zhou, Z., Liu, H., Ju, H., Chen, H., Jin, H., & Sun, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.01.026 · Cited by 39
Deletion of the gene for adiponectin accelerates diabetic nephropathy in the Ins2 +/C96Y mouse
Fang, F., Bae, E.-H., Hu, A., Liu, G. C., Zhou, X., Williams, V. R., Maksimowski, N. A., Lu, C., Konvalinka, A., John, R., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3605-9 · Cited by 37
Christensen, M. S., Jensen, J., Jakobsen, S., Jessen, N., Frøkiær, J., Kemp, B. E., Marciszyn, A. L., Li, H., Pastor‐Soler, N. M., Hallows, K. R., et al. (2016) · Scientific Reports · doi:10.1038/srep35952 · Cited by 37 · cited 1×
“…reduce inflammatory markers and to promote an antioxidant response in mice that are deficient in the β1 subunit of AMPK and thus showed compromised AMPK activity in the kidney 146 , suggesting that metformin might also act through AMPK-independent mechanisms to confer protection from kidney damage.”
Ye, C., Kong, L., Zhao, Z., Li, M., Wang, S., Lin, H., Xu, Y., Lu, J., Chen, Y., Xu, Y., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab633 · Cited by 37 · cited 1×
“Mendelian randomization studies have demonstrated causal associations between obesity and CKD 6 .”
MacLaughlin, H. L., Hall, W. L., Patel, A. G., Blacklock, R. M., Swift, P. A., Phanish, M. K., Dew, T. K., Chowdhury, P., Sanders, T. A. B., & Macdougall, I. C. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.06.011 · Cited by 35 · cited 1×
“Following sleeve gastrectomy in individuals with moderate to severe CKD, reductions in proteinuria and insulin resistance were associated with increased levels of adiponectin and decreased levels of leptin 59 .”
Sen, T., Li, J., Neuen, B. L., Arnott, C. G., Neal, B., Perkovic, V., Mahaffey, K. W., Shaw, W., Canovatchel, W., Hansen, M. K., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021661 · Cited by 35 · cited 1×
“GDF15 levels were found to modestly decrease with canagliflozin treatment in individuals in the CANVAS trial 161 .”
Lyu, X., Lyu, T., Wang, X., Zhu, H., Pan, H., Wang, L., Yang, H., & Gong, F. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6616693 · Cited by 33 · cited 1×
“Greater weight loss is observed in patients treated with metformin and GLP1RA combination therapy than in those treated with metformin monotherapy 159 , while metformin and dapagliflozin together elicit greater weight loss than either treatment alone in individuals with obesity and metabolic…”
Evolution of peptide YY analogs for the management of type 2 diabetes and obesity
Chen, W., Binbin, G., Lidan, S., Zhou, Q., & Han, J. D. J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106808 · Cited by 31 · cited 1×
“Similarly, the combination of semaglutide with a peptide YY analogue (NNC0165-1875), which acts as an agonist on the NPY receptor type 2 (Y2R) to centrally regulate food intake 122 , has demonstrated efficacy in murine models, and has recently been investigated in humans (NCT04969939).”
BOLD magnetic resonance imaging in nephrology
Hall, M. E., Jordan, J. H., Juncos, L. A., Hundley, W. G., & Hall, J. E. (2018) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s112299 · Cited by 29 · cited 1×
“…(NCT05536804), aim to provide more comprehensive information on the potential mechanism(s) of renal benefit of GLP1RAs, including blood oxygen level-dependent MRI of the kidneys, which measures renal tissue deoxyhaemoglobin levels as a functional, validated measure of renal hypoxia 123 .”
Sargeant, J. A., King, J. A., Yates, T. E., Baldry, E. L., Bodicoat, D. H., Chatterjee, S., Edwardson, C. L., Gray, L. J., Poulin, B., Waheed, G., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14721 · Cited by 29 · cited 1×
“Furthermore, the SEESAW trial in individuals with overweight or obesity and T2DM found no alterations in subjective measures of appetite or postprandial appetite-regulatory gut peptides (total peptide YY, GLP1 and acylated ghrelin) after 24 weeks of empagli-flozin treatment 80 .”
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
Cheng, L., Fu, Q., Zhou, L., Fan, Y., Liu, F., Fan, Y., Zhang, X., Lin, W., & Wu, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-03773-z · Cited by 27 · cited 1×
“…than in those treated with metformin monotherapy 159 , while metformin and dapagliflozin together elicit greater weight loss than either treatment alone in individuals with obesity and metabolic syndrome, suggesting that distinct weight-lowering mechanisms act additively or synergistically 160 .”
Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human
Dolo, P. R., Yao, L., Liu, P. P., Widjaja, J., Song, M., Li, C., & Zhu, X. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.01.041 · Cited by 26 · cited 8×
“Large meta-analyses have found that elevated BMI, waist circumference and waist to height ratio are independent risk factors associated with loss of kidney function (referring to the overall role of the kidney in maintaining homeostasis) and mortality in individuals with normal or reduced estimated glomerular filtrati…”
InfluentialBiology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Self-citationGrowth differentiation factor 15 is decreased by kidney transplantation
Connelly, P. W., Yan, A. T.-K., Nash, M. M., Lok, C. E., Gunaratnam, L., & Prasad, G. V. R. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.07.013 · Cited by 19 · cited 2×
“Conversely, in patients who had undergone kidney transplantation, a decrease in GDF15 was observed 1 year after the procedure 152 .”
GDF15 analogs as obesity therapeutics
Breit, S. N., Brown, D. A., & Tsai, V. W.-W. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.002 · Cited by 19 · cited 2×
“…studies, potentially owing to subtle differences between the synthetic long-acting agonist and endogenous GDF15–GFRAL signalling, a compensatory decrease in energy expenditure, or other experimental design factors such as standardized meals that do not reflect typical eating behaviour 151,158 .”
Rajeev, S. P., Roberts, C. A., Brown, E. E., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Boyland, E. J., Kemp, G. J., Perry, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15257 · Cited by 17 · cited 1×
“The ENERGIZE trial found that a reduction in body weight and liver fat in 52 patients treated with dapagliflozin was not associated with compensatory adaptations in food intake or energy expenditure 79 .”
Salman, A., Shaaban, H. E., Salman, M. A., Nasr, S. M. S. E., Soliman, A. M., Salem, A., El-Din, M. T., Mikhail, H. M. S., El-Domiaty, H. F., Allah, N. A., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s304929 · Cited by 10 · cited 1×
“were seen to increase as soon as 1 month following sleeve gastrectomy and were negatively associated with changes in BMI 154,155 .”
Anesten, F., Mishra, D., Gasull, A. D., Engström, L., Bellman, J., Pálsdóttir, V., Zhang, F., Trapp, S., Skibicka, K. P., POUTANEN, M. H., et al. (2019) · Neuroendocrinology · doi:10.1159/000499693 · Cited by 8
Gfral-expressing Neurons Suppress Food Intake via Aversive PathwaysPreprint
Sabatini, P. V., Frikke‐Schmidt, H., Arthurs, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.11.088773 · Cited by 7 · cited 1×
“GFRAL is almost exclusively expressed in the area postrema and nucleus of the solitary tract of the hindbrain 132–135, 138 and Similar to GLP1RAs, GDF15 alters food preferences in individuals with obesity and contributes to reduced caloric intake in mice 131,132,139,140 .”
Morbid obesity and hypertension: The role of peri-renal fat
Ricci, M. A., Scavizzi, M., Ministrini, S., Migliola, E. N., VUONO, S. D., & Lupattelli, G. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.212 · Cited by 6
Seyfried, F., Hoffmann, A., Rullmann, M., Schlegel, N., Otto, C., & Hankir, M. K. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113534 · Cited by 6
Zhou, Z., Liu, H., Ju, H., Chen, H., Li, L., Jin, H., & Sun, M. (2022) · doi:10.37766/inplasy2022.10.0076 · Cited by 1 · cited 1×
“However, in a meta-analysis of 14 studies, elevated levels of GDF15 were also found to be associated with CKD progression 149 .”
Cited by
Romagnani, P., Agarwal, R., Chan, J. C. N., Levin, A., Kalyesubula, R., Karam, S., Nangaku, M., Rodríguez-Iturbe, B., & Anders, H.-J. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00589-9 · Cited by 184
Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine · doi:10.1038/s41591-024-03374-z · Cited by 166
“Indeed, volume expansion, CKD and greater burden of hypertension best distinguish individuals from obesity-related HFpEF from age, sex and BMI-matched patients with obesity but no HF 9 .”
InfluentialXie, K., Cao, H., Ling, S., Zhong, J., Chen, H., Chen, P., & Huang, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1526482 · Cited by 149
“Research has shown that obesity is a key driver of CKD progression, with mechanisms including hemodynamic changes, in fl ammation, oxidative stress, and activation of the renin-angiotensin-aldosterone system (RAAS) (41).”
AMPK at the interface of nutrient sensing, metabolic flux and energy homeostasis
Smith, T. K. T., Townsend, L. K., Smiles, W. J., Oakhill, J. S., Fullerton, M. D., & Steinberg, G. R. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01442-3 · Cited by 65
“In diabetes-associated CKD, reduced AMPK activity is linked to impaired kidney function and increased renal hypertrophy in animal models 284,285 .”
Dong, B., Zhao, Y., Wang, J., Lu, C., Chen, Z., Ma, R., Bi, H., Wang, J., Wang, Y., Ding, X., et al. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2403645 · Cited by 49
“…kidney function screening and provision of renal protective treatments, such as aCE inhibitors and SGlt2 inhibitors, could reduce CKd incidence [32]. diabetic nephropathy (dn) is a complication of diabetic microvascular disease and has become one of the leading causes of ESRd. to prevent the…”
Metadata
- Authors
- Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- Corresponding author
- Cherney, David Z. I.
- Lam, Tony K. T.
- Venue
- Nature Reviews Endocrinology
- Published
- 2024-02-13
- Volume
- 20
- Issue
- 6
- Pages
- 321-335
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W4391773493
- Cited by
- 91
- References
- 178
- Citations by year
- 2026: 26 · 2025: 47 · 2024: 18
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › GDF15 and Related Biomarkers
- Keywords
- obesity, chronic kidney disease, kidney-brain axis, growth differentiation factor 15, bariatric surgery, diabetes mellitus, SGLT2 inhibitors, incretin-based therapy, metformin, body weight regulation, renal function
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Body Weight, Humans, Kidney, Obesity, Bariatric Surgery, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.